Subscribe to RSS
DOI: 10.1055/s-2008-1027628
© Georg Thieme Verlag KG Stuttgart · New York
Splenic Rupture in Systemic Amyloidosis – Case Presentation and Review of the Literature
Milzruptur bei systemischer Infiltrationskrankheit – ein Fallbericht und Übersicht der LiteraturPublication History
manuscript received: 6.12.2007
manuscript accepted: 17.6.2008
Publication Date:
11 March 2009 (online)

Zusammenfassung
Einleitung: Die Milzruptur und Blutung in den Bauchraum ist eine äußerst ungewöhnliche und seltene Komplikation einer internistischen Krankheit. Mögliche Ursachen für eine solche Komplikation sind Blut-, Entzündungs- oder Infiltrationskrankheiten, welche die Milz affizieren. Die Milzvergrößerung ist ein Faktor, der das Risiko einer Milzruptur signifikant erhöht. Fallbericht: Die Autoren stellen einen 52-jährigen Patienten mit festgestellter systemischer Amyloidose vor. Zuvor wurde er wegen einer undefinierten Leberkrankheit und Anämie behandelt, die bei der Behandlung pathologischer Wirbelbrüche festgestellt wurden. Leider willigte er während der ersten Behandlung in eine Leberbiopsie zur Bestimmung der Ätiologie der Krankheit nicht ein. Die systemische Infiltrationskrankheit wurde posthum bestimmt; die Milz sowie andere Organe waren betroffen. Es werden jene Formen der Amyloidose beschrieben, welche gewöhnlich einen ungünstigen Krankheitsverlauf bedeuten. Schlussfolgerung: Es wird ein Patient mit einer seltenen Form von Amyloidose und einer tödlichen Komplikation, Milzruptur, vorgestellt.
Abstract
Introduction: Splenic rupture and hemorrhage into the abdominal cavity is an extremely unusual and rare complication of internal disease. Hemopathies, inflammatory or infiltrative diseases affecting the spleen are possible causes for such a complication. Splenomegaly is a factor, which may significantly increase the risk of rupture. Case Report: The authors present the case of a 52-year-old patient with established systemic amyloidosis. In the past he had received treatment for undefined hepatic disease and anemia, which was established during the treatment of pathological vertebral fractures. Unfortunately, during the initial treatment he did not consent to a liver biopsy, which would have determined the etiology of the disease. Systemic infiltrative disease, affecting the spleen and other organs, was confirmed posthumously. Described are those forms of amyloidosis which usually represent an unfavorable course of the disease. Conclusion: Presented is a patient with a rare form of primary amyloidosis and fatal complication, spleenic rupture.
Schlüsselwörter
Milz - Ruptur - Infiltrationskrankheit - Leber - Amyloidose - Komplikationen
Key words
spleen - rupture - infiltrative diseases - liver - amyloidosis - complications
References
- 1
Autry J R, Weitzner S.
Hemangiosarcoma of spleen with spontaneous rupture.
Cancer.
1975;
35
534-539
MissingFormLabel
- 2
Andrews D F, Hernandez R, Grafton W. et al .
Pathologic rupture of the spleen in non-Hodgkin’s lymphoma.
Arch Intern Med.
1980;
140
119-120
MissingFormLabel
- 3
Von der Walde J, Mashiah A, Berrebi A.
Spontaneous rupture of the spleen in hairy cell leukemia.
Clin Oncol.
1981;
7
241-244
MissingFormLabel
- 4
Okazaki K, Moriyasu F, Shiomura T. et al .
Spontaneous rupture of the spleen and liver in amyloidosis – a case report and review
of the literature.
Gastroenterol Jpn.
1986;
21
518-524
MissingFormLabel
- 5
Simansky D A, Schiby G, Dreznik Z. et al .
Rapid progressive dissemination of hemangiosarcoma of the spleen following spontaneous
rupture.
World J Surg.
1986;
10
142-145
MissingFormLabel
- 6
Gertz M A, Kyle R A.
Hepatic amyloidosis, primary (AL), immunoglobulin light chain: the natural history
in 80 patients.
Am J Med.
1988;
85
73-80
MissingFormLabel
- 7
Gertz M A, Kyle R A.
Primary systemic amyloidosis – a diagnostic primer.
Mayo Clin Proc.
1989;
64
1505-1519
MissingFormLabel
- 8
Hawkins P N, Lavender J P, Pepys M B.
Evaluation of systemic amyloidosis by scintigraphy with 123 I-labeled serum amyloid
P component.
N Engl J Med.
1990;
323
508-513
MissingFormLabel
- 9
Patel S A, al-Haddadin D, Schopp J. et al .
Gastrointestinal manifestations of amyloidosis: a case of diverticular perforation.
Am J Gastroenterol.
1993;
88
578-582
MissingFormLabel
- 10
Serra L, Poppi M C, Criscuolo M. et al .
Primary systemic amyloidosis with giant hepatomegaly and portal hypertension: a case
report and a review of the literature.
Ital J Gastroenterol.
1993;
25
435-438
MissingFormLabel
- 11
Herrera G A, Sanders P W, Reddy B V. et al .
Ultrastructural immunolabeling: a unique diagnostic tool in monoclonal light chain-related
renal diseases.
Ultrastruct Pathol.
1994;
18
401-416
MissingFormLabel
- 12
Gertz M A, Kyle R A.
Amyloidosis: prognosis and treatment.
Semin Arthritis Rheum.
1994;
24
124-138
MissingFormLabel
- 13
Pascali E.
Diagnosis and treatment of primary amyloidosis.
Crit Rev Oncol Hematol.
1995;
19
149-181
MissingFormLabel
- 14
Skinner M, Anderson J J, Simms R. et al .
Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan,
prednisone, and colchicine versus colchicine alone.
Am J Med.
1996;
100
290-298
MissingFormLabel
- 15
Halm U, Berr F, Eggers E. et al .
Primary amyloidosis of the gastrointestinal tract and liver – two case reports.
Z Gastroenterol.
1997;
35
131-137
MissingFormLabel
- 16
Kyle R A, Gertz M A, Greipp P R. et al .
A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and
prednisone, and melphalan, prednisone, and colchicine.
N Engl J Med.
1997;
336
1202-1207
MissingFormLabel
- 17
Goss J A, Stribling R, Martin P.
Adult liver transplantation for metabolic liver disease.
Clin Liver Dis.
1998;
2
187-210
MissingFormLabel
- 18
Kyle R A, Gertz M A, Greipp P R. et al .
Long-term survival (10 years or more) in 30 patients with primary amyloidosis.
Blood.
1999;
93
1062-1066
MissingFormLabel
- 19
Sezer O, Niemoller K, Jakob C. et al .
Novel approaches to the treatment of primary amyloidosis.
Expert Opin Investig Drugs.
2000;
9
2343-2350
MissingFormLabel
- 20
Anesi E, Palladini G, Perfetti V. et al .
Therapeutic advances demand accurate typing of amyloid deposits.
Am J Med.
2001;
111
243-244
MissingFormLabel
- 21
Comenzo R L.
Primary systemic amyloidosis.
Curr Treat Options Oncol.
2000;
1
83-89
MissingFormLabel
- 22
Gertz M A, Rajkumar S V.
Primary systemic amyloidosis.
Curr Treat Options Oncol.
2002;
3
261-271
MissingFormLabel
- 23
Sanchorawala V, Wright D G, Seldin D C. et al .
Low dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.
Br J Haematol.
2002;
117
886-889
MissingFormLabel
- 24
Bernstein C N.
Treatment of the extraintestinal manifestations of inflammatory bowel disease.
Curr Gastroenterol Rep.
2002;
4
513-516
MissingFormLabel
- 25
Gertz M A, Lacy M Q, Dispenzieri A. et al .
Stem cell transplantation for the management of primary systemic amyloidosis.
Am J Med.
2002;
113
549-555
MissingFormLabel
- 26
Park M A, Mueller P S, Kyle R A. et al .
Primary (AI) hepatic amyloidosis: clinical features and natural history in 98 patients.
Medicine (Baltimore).
2003;
82
291-298
MissingFormLabel
- 27
Oran B, Wright D G, Seldin D C. et al .
Spontaneous rupture of the spleen in AL amyloidosis.
Am J Hematol.
2003;
74
131-135
MissingFormLabel
- 28
Nilsson M R.
Techniques to study amyloid fibril formation in vitro.
Methods.
2004;
34
151-160
MissingFormLabel
- 29
Solomon A, Weiss D T, Wall J S.
Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal
antibodies.
Cancer Biother Radiopharm.
2003;
18
853-860
MissingFormLabel
- 30
Palladini G, Perfetti V, Obici L. et al .
Association of melphalan and high-dose dexamethasone is effective and well tolerated
in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.
Blood.
2004;
103
2936-2938
MissingFormLabel
- 31
Buxbaum J N.
The systemic amyloidoses.
Curr Opin Rheumatol.
2004;
16
67-75
MissingFormLabel
- 32
Ekart R, Bevc S, Dajcman D. et al .
Sekundarna amiloidoza ob Crohnovi bolezni ter nefroticˇni sindrom: prikaz primera.
Zdrav Vestn.
2004;
73
177-179
MissingFormLabel
- 33
Leung N, Dispenzieri A, Fervenza F C. et al .
Renal response after high-dose melphalan and stem cell transplantation is a favorable
marker in patients with primary systemic amyloidosis.
Am J Kidney Dis.
2005;
46
270-277
MissingFormLabel
- 34
Shah K B, Inoue Y, Mehra M R.
Amyloidosis and the heart: a comprehensive review.
Arch Intern Med.
2006;
166
1805-1813
MissingFormLabel
- 35
Sirohi B, Powles R.
Epidemiology and outcomes research for MGUS, myeloma and amyloidosis.
Eur J Cancer.
2006;
42
1671-1683
MissingFormLabel
- 36
Palladini G, Perfetti V, Merlini G.
Therapy and management of systemic AL (primary) amyloidosis.
Swiss Med Wkly.
2006;
136
715-720
MissingFormLabel
- 37
Schiodt I, Duun E, Fischer T K. et al .
Fatal rupture of the spleen caused by infiltration of T-cell lymphoma.
Ann Hematol.
2000;
79
158-160
MissingFormLabel
- 38
Debnath D, Valerio D.
Atraumatic rupture of the spleen in adults.
J R Coll Surg.
2002;
47
437-445
MissingFormLabel
- 39
Biswas S, Keddington J, McClanathan J.
Large B-cell lymphoma presenting as acute abdominal pain and spontaneous splenic rupture.
A case report and review of relevant literature.
World J Em S.
2006;
1
35
MissingFormLabel
- 40
Aydinli B, Ozturk G, Balik A A. et al .
Spontaneous rupture of the spleen in secondary amyloidosis: A patient with rheumatoid
arthritis.
Amyloid.
2006;
13
160-163
MissingFormLabel
- 41
Goddard S L, Chesney A E.
Pathological splenic rupture: a rare complication of chronic myelomonocytic leukemia.
Am J Hematol.
2007;
82
405-408
MissingFormLabel
Prof. Pavel Skok
Gastroenterology and Endoscopy, University Clinical Centre Maribor
Ljubljanska 5
2000 Maribor
Slovenia
Phone: ++ 3 86/2/23 26 82
Fax: ++ 3 86/2/3 31 23 93
Email: pavel.skok@ukc-mb.si